Novo Nordisk(NVO) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, the company achieved a 10% sales growth and a 6% operating profit growth, with obesity care sales increasing from DKK 6 billion in 2019 to DKK 82 billion in 2025 [4][10] - The gross margin decreased to 81% from 84.7% in 2024, influenced by amortizations and restructuring costs [34] - Operating profit decreased by 1% in DKK but increased by 6% at constant exchange rates, reflecting higher sales and distribution costs [34] Business Line Data and Key Metrics Changes - GLP-1 sales in diabetes increased by 6%, with U.S. operations growing by 5% and international operations by 7% [10] - Obesity care sales surged by 31%, driven by both U.S. operations (15% growth) and international operations (73% growth) [10] - Rare disease sales increased by 9%, primarily due to the uptake of rare endocrine disorder products [11] Market Data and Key Metrics Changes - The global GLP-1 market grew over 30% in 2025, with Novo Nordisk maintaining a 62% volume market share in GLP-1 products [10][12] - In China, GLP-1 diabetes sales decreased by 5%, negatively impacted by wholesaler inventory movements [12] - Wegovy sales reached DKK 28 billion in 2025, growing 134% after being launched in 35 new countries [13] Company Strategy and Development Direction - The company is focusing on core therapeutic areas of obesity and diabetes, with plans to expand obesity and diabetes markets through new online channels and partnerships [4][10] - The company aims to introduce new strategic aspirations in September 2026, following the conclusion of the 2025 strategic aspirations [43][44] - The company is investing in expanding manufacturing capacity and R&D pipeline, with around DKK 60 billion allocated for manufacturing and DKK 30 billion for R&D [35][36] Management's Comments on Operating Environment and Future Outlook - Management acknowledged significant challenges in 2025 but emphasized resilience and commitment to meet unmet needs in diabetes, obesity, and rare diseases [43] - The company anticipates pricing headwinds in 2026 but aims to pursue volume opportunities in obesity and diabetes [6][39] - The outlook for 2026 includes expected sales growth of -5% to -13% at constant exchange rates, influenced by competitive dynamics and pricing strategies [39][40] Other Important Information - The company returned over DKK 300 billion to shareholders since 2019, with a proposed final dividend of DKK 7.95 for 2025 [4][37] - Changes in the executive management team were announced, with new appointments expected to enhance leadership capabilities [6][9] Q&A Session Summary Question: Guidance breakdown between volumes and price - The company indicated that the U.S. sales decline is driven by price reductions and investments in market access, with expectations for mid-single-digit growth in international operations [47][50] Question: Medicare unlock speed - Management expects a gradual ramp-up in Medicare Part D coverage for Wegovy, with limited benefits anticipated in 2026 and a larger impact expected in 2027 [52] Question: Supply risk for Wegovy pill - The company is monitoring supply capabilities to meet demand for the Wegovy pill, with current capacity expected to service demand through the year [83] Question: CagriSema and REDEFINE 4 trial - Management clarified that REDEFINE 4 is designed to compare CagriSema and tirzepatide, with flexible dosing similar to previous trials [77]